Lymphoblastic – News & Updates

The USFDA Grants Orphan Drug Designation to CT120 a Novel CAR T-Cell Therapy of IASO Biotherapeutics for Acute Lymphoblastic Leukemia

adminNovember 30, 20210973 views

KEYPOINTS: The FDA has granted orphan drug designation (ODD) to CT120 for the treatment of acute lymphoblastic leukemia, a novel chimeric antigen…

Zydus Cadila receives USFDA Final Approval for Nelarabine Injection a Therapeutically Generic Version of Arranon injection.

adminNovember 19, 20210858 views

KEYPOINTS: Zydus Cadila has received final approval from the US FDA to market Nelarabine injection 250MG/50ML in the United States. Zydus Pharmaceuticals…

Novartis’s BLA has been accepted by US FDA & EMA for Kymriah (Tisagenlecleucel) to treat patients with relapsed or refractory follicular lymphoma.

adminOctober 28, 202101.1k views

Novartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…